Results 11 to 20 of about 927,052 (258)

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. [PDF]

Immunotargets Ther, 2021
Axial spondyloarthritis (axSpA) describes a group of chronic inflammatory rheumatic diseases primarily involving the axial skeleton. IL-17 is involved in the pathogenesis of numerous inflammatory diseases, including inflammatory arthritis. Until a few years ago, the only biological agents licensed for the treatment of axSpA and nr-axSpA were TNF ...
Atzeni F, Carriero A, Boccassini L, D'Angelo S.   +3 more
europepmc   +8 more sources

Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. [PDF]

Case Rep Dermatol, 2020
Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant ...
Pangilinan MCG, Sermswan P, Asawanonda P.   +2 more
europepmc   +5 more sources

Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS. [PDF]

Front Pharmacol, 2020
Although the major alterations associated with asthma are related to the airways, there is also evidence of the importance of peribronchial vascular inflammation and remodeling in its pathophysiology.To determine the effects of anti-IL-17 therapy on peribronchial vessels of an asthma model exacerbated by lipopolysaccharide.We evaluated several factors,
Camargo LDN, Dos Santos TM, de Andrade FCP, Fukuzaki S, Dos Santos Lopes FDTQ, de Arruda Martins M, Prado CM, Leick EA, Righetti RF, Tibério IFLC.   +9 more
europepmc   +5 more sources

Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis. [PDF]

Front Immunol, 2020
Current treatments for chronic immune-mediated diseases such as psoriasis, rheumatoid arthritis, or Crohn's disease commonly rely on cytokine neutralization using monoclonal antibodies; however, such approaches have drawbacks. Frequent repeated dosing can lead to the formation of anti-drug antibodies and patient compliance issues, and it is difficult ...
Shores LS, Kelly SH, Hainline KM, Suwanpradid J, MacLeod AS, Collier JH.   +5 more
europepmc   +5 more sources

Anti-IL-17 therapy restricts and reverses late-term corneal allorejection. [PDF]

J Immunol, 2015
Abstract Corneal allograft rejection has been described as a Th1-mediated process involving IFN-γ production. However, recent evidence also implicated IL-17 as being involved in acute corneal allograft responses. Our data support that IL-17 is involved in early acute corneal allograft acceptance.
Yin XT, Zobell S, Jarosz JG, Stuart PM.
europepmc   +4 more sources

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

BMC Oral Health, 2021
Background Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated
Bruna Lavinas Sayed Picciani, Arkadiusz Dziedzic, Juliana Tristão Werneck, Marcello Alves Marinho, Thaylla Núñez Amin Dick, Nara Regina Quintanilha, Eliane Pedra Dias   +6 more
doaj   +1 more source

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Frontiers in Pharmacology, 2019
Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.
Lazaros I. Sakkas, Efterpi Zafiriou, Dimitrios P. Bogdanos   +2 more
doaj   +1 more source

Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model. [PDF]

Korean J Intern Med, 2018
The co-occurrence of obesity aggravates asthma symptoms. Diet-induced obesity increases helper T cell (TH) 17 cell differentiation in adipose tissue and the spleen. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin can potentially be used to treat asthma in obese patients by inhibiting interleukin 17 (IL-17) expression.
Liang L, Hur J, Kang JY, Rhee CK, Kim YK, Lee SY.   +5 more
europepmc   +4 more sources

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Psoriasis: Targets and Therapy, 2022
Angelo Ruggiero, Luca Potestio, Elisa Camela Snr, Gabriella Fabbrocini, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of ...
Ruggiero A, Potestio L, Camela snr E, Fabbrocini G, Megna M   +4 more
doaj  

Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy

BMC Rheumatology, 2023
Background Behcet’s disease (BD) is a systemic disease characterized by recurrent oral and genital ulcers. The underlying disease pathway likely involves interleukin (IL)-17 A, a proinflammatory cytokine that is implicated in Behcet’s uveitis ...
Frances Sze Kei Sun, Nicole Sau Yan Chiu, Ho Yin Chung   +2 more
doaj   +1 more source